A metered dose inhaler having part or all of its internal metallic surfaces coated with one or more fluorocarbon polymers, in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising salmeterol, or a salt thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents and one or more excipients.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. application Ser. No. 08/583,332 filed on Jan. 5, 1996, now abandoned, which is a continuation-in-part of application Ser. No. 08/422,370 filed on Apr. 14, 1995 (now abandoned). This application is also a continuation of PCT International Application No. PCT/US96/05005 filed on Apr. 10, 1996, which designated the United States, which is a continuation-in-part of application Ser. No. 08/583,332, filed Jan. 5, 1996 (now abandoned), which is a continuation-in-part of application Ser. No. 08/422,370, filed Apr. 14, 1995 (now abandoned).
The invention relates to a pharmaceutical aerosol formulation comprising a surfactant that is an alkyl-polyglycoside of formula I, wherein DP is the average degree of polymerisation and has a value of from 1 to 4, and R is an alkyl chain or a mixture of alkyl chains having a chain length of from 6 to 22 carbon atoms; or a derivative thereof for the administration of a medicament for inhalation.
The present invention relates to a combination comprising (a) an adenosine A.sub.2a receptor agonist as define herein and (b) an adrenergic .beta.2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.
The present invention relates to a combination comprising (a) an adenosine A.sub.2a receptor agonist as defined herein and (b) an adrenergic .beta.2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.
The present invention relates to compounds of the formula ##STR1## and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds as adenosine A2a receptor agonists.
A medicinal aerosol steroid solution formulation product with enhanced chemical stability. The steroid is a 20-ketosteroid having an OH group at the C-17 or C-21 position and the aerosol container has a non-metal interior surface which has been found to reduce chemical degradation of such steroids.
